Smith & Nephew gains from investments in wound care, emerging markets

Smith & Nephew ($SNN) has turned its eye toward wound care and emerging markets in recent months, and the strategy is paying off. The U.K. medical device company reported 4.4% growth in the second quarter, to $1.07 billion, thanks to healthy results in both areas. The company's performance matched the average of 12 analyst estimates, Bloomberg reports. Gains in international markets and negative pressure wound therapy helped offset a slow quarter in Smith & Nephew's orthopedic reconstruction business, CEO Olivier Bohuon noted in a statement. Last year, the company snatched up wound care company Healthpoint Biotherapeutics for $782 million. In May, Smith & Nephew invested in an Indian orthopedic trauma device company and launched a $300 million share buyback. More

Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.